Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy. U.S. District Judge Allison Burroughs said in a post-trial ruling that the Teva patents covering the use of antibodies to inhibit headache-causing peptides were invalid. "The Court does not reach this decision nor overturn a jury verdict lightly," Burroughs said.
If you're looking for dividend stocks that can boost your portfolio returns, you should consider high-quality companies that can pay consistent and growing dividends. Two dividend stocks that stand out as strong buys right now are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Here's why these two top-notch dividend stocks are still worth buying, even though they sport premium valuations.
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.